New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2012
16:38 EDTDIS, ABT, VRTX, CECO, CTSH, TPXOn The Fly: Closing Wrap
Stocks on Wall Street were mixed, as investors had a muted reaction to the anti-austerity backlash evidenced in two elections in Europe. Stock futures pointed to a lower open throughout the pre-market trading session but moved off their low prior to the opening bell. The futures action led to a lower but stable open with the market essentially hitting its lows soon after the open. The market began to drift off its lows after the first hour of trading and by midday made it back to positive ground. The market continued to drift for most the remainder of the session until a downturn into the close pushed the S&P and Nasdaq back down to finish the day near the flat line... ECONOMIC EVENTS: In the U.S., consumer credit increased by $21.36B in March, versus expectations of an increase of $9.8B. In Europe, Francois Hollande defeated Nicolas Sarkozy in France's presidential election and voting in Greece’s general election showed a dramatic swing toward anti-austerity groups and away from the pro-Europe parties... COMPANY NEWS: Disney's (DIS) "The Avengers" set U.S. records with its $200M opening weekend, powering the company's shares 2% higher... Abbott Labs (ABT) announced it reached a settlement and will pay $1.6B in connection with its marketing of Depakote... MAJOR MOVERS: Among the notable gainers were Vertex Pharma (VRTX), up $20.71, or 55.36%, to $58.12, amid at least three upgrades and a number of price target increases after the company reported interim data from a Phase 2 study of a combination therapy for certain cystic fibrosis patients, and Career Education (CECO), up 56c, or 8.70%, to $7.00, after the Accrediting Council for Independent Colleges and Schools removed its show-cause directive on all 71 Career Education campuses accredited by the body and the company said four of its campuses were placed on probation. Noteworthy losers included Cognizant (CTSH), down $13.35, or 19.16%, to $56.31, after the company's earnings beat consensus but it said its revising its guidance to be more conservative after seeing slower-than-expected acceleration in demand, and Tempur-Pedic (TPX), down $8.42, or 14.85%, to $48.29, as Raymond James said in a note to investors that the company will offer a discount on one of its most profitable mattresses, the Cloud Supreme, which the firm said was unusual for the company... INDICES: The Dow lost 29.74, or 0.23%, to 13,008.53; the Nasdaq rose 1.42, or 0.05%, to 2,957.76; and the S&P 500 added 0.48, or 0.04%, to 1,369.58.
News For DIS;ABT;VRTX;CECO;CTSH;TPX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 23, 2014
06:22 EDTABTMylan, Abbott enter into amendment, still see deal closing in 1Q15
Subscribe for More Information
October 22, 2014
13:06 EDTDISEarnings Preview: Comcast reporting Q3 results as Time Warner deal progressing
Comcast (CMCSA, CMCSK) is set to report third quarter earnings before the market open on Thursday, October 23, with a conference call scheduled for 8:30 am ET. Comcast is a diversified media company that operates the NBC family of networks and Universal Pictures, among other cable, internet, and voice services. On February 13, Comcast announced plans to merge with Time Warner Cable (TWC) in a deal valued at $45.2B. EXPECTATIONS: Analysts are looking for earnings per share of 71c on revenue of $16.82B, according to First Call. The consensus range for EPS is 64c-76c on revenue of $16.5B-$17.17B. LAST QUARTER: Comcast reported second quarter EPS of 75c against estimates for 72c, on revenue of $16.84B against estimates for $16.95B. TIME WARNER CABLE DEAL: On August 17, The Wall Street Journal reported that the Federal Communications Commission said that one issue it must decide as it reviewed the proposed acquisition of Time Warner Cable is whether to allow Comcast to continue Time Warner Cable's arrangement to handle programming and technology acquisitions for cable operator Bright House Networks. On August 26, Engadget reported that Netflix (NFLX) filed a formal protest against the Time Warner Cable deal, saying that the merger would result in "serious public interest harm" and that a combined cable giant would have a huge amount of leverage over it and rivals such as Hulu. Hulu is a joint venture owned by Comcast along with Disney (DIS) and 21st Century Fox (FOX,FOXA). The New York Post reported on September 8 that Discovery (DISCA) believed Comcast's takeover of Time Warner Cable would give the merged entity an unfair advantage over programmers. That same day, Reuters said a proxy statement detailed that Time Warner Cable employees would split $416M if the merger deal with Comcast did not transpire. At the Goldman Sachs Communacopia Conference on September 10, Comcast said that it has made "a lot of progress" on the shareholder approval process for the Time Warner Cable deal, but expected the agreement to be finalized in early fiscal year 2015 versus the previous guidance of late 2014. The company expects the Time Warner Cable merger to generate $1.5B in operating expense synergies. On September 16, Comcast said at the Media, Communications and Entertainment Conference that it would reveal its capital plan at the close of the Time Warner Cable deal and noted at that time that "everything was on track" regarding the merger. The Wall Street Journal reported on September 30 that the FCC pushed for media companies to submit details of their programming agreements with Comcast prior to the Time Warner Cable deal. The FCC announced three days later that it extended time for the companies to file their replies on Comcast regarding the merger. On October 8, Comcast Shareholders approved stock issuance for the Time Warner Cable deal and the next day, Time Warner Cable stockholders approved the Comcast merger deal. STREET RESEARCH: Analysts remained fairly quiet on Comcast throughout the quarter. On September 9, UBS raised its price target on Comcast to $72 from $60 given its strong underlying fundamentals and the expected free cash flow accretion from the Time Warner Cable deal. The firm also said it expected Comcast to accelerate its stock buyback and increase its dividend. UBS kept its Buy rating on the stock. On October 17, Goldman Sachs said that Comcast was its top large cap pick into the earnings report given steady fundamentals, moderated expectations, and valuation. The firm maintained the stock with a Buy rating and a $64 price target. PRICE ACTION: Since the first day of trade following its Q2 report on July 22, shares of Comcast are down about 3.5%. Since it announced its deal with Time Warner Cable on February 13, shares of the media company have fallen just under 6%. In late-morning trade ahead of tomorrow’s Q3 report, shares of Comcast are down fractionally.
09:24 EDTABTAbbott says on track for another year of double digit adjusted EPS growth
Subscribe for More Information
09:21 EDTABTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
09:16 EDTABTAbbott sees Q4 reported sales growth in high single digits
Subscribe for More Information
09:14 EDTABTAbbott sees FY14 operational sales growth in the mid single digits
Sees foreign exchange to have negative impact of approx. 2% on FY reported sales, somewhat more negative than previous expectations. Sees FY14 reported sales growth in low to mid single digits. Sees FY gross margin ratio about 55% of sales. Comments made on the Q3 earnings conference call.
08:04 EDTABTAbbott raises FY14 adjusted EPS view to $2.25-$2.27 from $2.19-$2.29
Subscribe for More Information
07:37 EDTABTAbbott sees Q4 EPS excl items 68c-70c, consensus 70c
Subscribe for More Information
07:36 EDTABTAbbott reports Q3 Nutrition revenue $1.79B, Q3 Diagnostics revenue $1.19B
Subscribe for More Information
07:34 EDTABTAbbott reports Q3 EPS 62c, consensus 59c
Subscribe for More Information
05:37 EDTVRTXVertex approval could add 500 more patients, says Piper Jaffray
Subscribe for More Information
October 21, 2014
16:49 EDTVRTXVertex: FDA Advisory Committee recommends approval of KALYDECO
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration’s Pulmonary Allergy Drugs Advisory Committee voted 13-2 to recommend approval of KALYDECO in people with cystic fibrosis ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory gene, which is the indication being reviewed by the FDA.
15:35 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
15:25 EDTVRTXPanel backs approval for Vertex CF drug in R117H mutation, Bloomberg says
Subscribe for More Information
15:18 EDTVRTXPanel votes Vertex CF drug safe, works for R117H mutation, Bloomberg reports
Subscribe for More Information
07:44 EDTABTAbbott volatility elevated into Q3 and outlook
Subscribe for More Information
07:11 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committe to hold a meeting
Subscribe for More Information
October 17, 2014
10:27 EDTVRTXVertex FDA panel expected to be positive at Piper Jaffray
Subscribe for More Information
10:26 EDTVRTXFDA panel asked to consider benefit of Vertex drug in younger CF patients
Subscribe for More Information
10:16 EDTCECOHigh option volume stocks
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use